Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) improved with gilteritinib, a single-agent second-generation FLT3 tyrosine kinase inhibitor (TKI), compared with standard of care. In this trial, the response rate with...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertoli, Sarah, Dumas, Pierre-Yves, Bérard, Emilie, Largeaud, Laetitia, Bidet, Audrey, Delabesse, Eric, Tavitian, Suzanne, Gadaud, Noémie, Leguay, Thibaut, Leroy, Harmony, Rieu, Jean-Baptiste, Vial, Jean-Philippe, Vergez, François, Lechevalier, Nicolas, Luquet, Isabelle, Klein, Emilie, Sarry, Audrey, De Grande, Anne-Charlotte, Récher, Christian, Pigneux, Arnaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226007/
https://www.ncbi.nlm.nih.gov/pubmed/32218221
http://dx.doi.org/10.3390/cancers12040773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226007/
https://www.ncbi.nlm.nih.gov/pubmed/32218221
http://dx.doi.org/10.3390/cancers12040773

Ejemplares similares